EMA Recommends Extending Indications for Lisocabtagene Maraleucel By Ogkologos - November 12, 2025 23 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of adult patients with relapsed or refractory mantle cell lymphoma Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR Health inequalities: “We have a moral duty to reduce them” February 15, 2022 Cómo pueden sobrellevar la ansiedad provocada por una exploración las personas... August 4, 2022 Making Cancer Clinical Trials Available to More Patients March 7, 2019 Palbociclib Plus Endocrine Therapy Does Not Improve PFS over Capecitabine in... January 12, 2021 Load more HOT NEWS FDA Approves Pembrolizumab with Chemoradiotherapy for FIGO 2014 Stage III-IVA Cervical... Foodie Friday: Couscous Salad After Lung Cancer Screening, Follow-Up Procedures May Be Riskier than Thought Daughter Donates Hair to Mother After She Was Diagnosed with Stage...
